Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy -October 16, 2023 at 02:09 am EDT
NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance...
Oncolys Biopharma Japan Esophageal Society Primary Endpoint Clinical Trial Radiation Combination Therapy Local Complete Response
Source: marketscreener.com